Clinical Trial Update: To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, pharmacokinetics and efficacy of HRS-6209 in HR-positive/HER2-negative breast cancer. The trial is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HRS-6209 (HRS-6209)

Snippet

Sponsor: Atridia Pty Ltd. | Conditions: Breast Cancer | Phase 1 | Status: NOT_YET_RECRUITING